Compare Medpace Holdings Inc (MEDP) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Palantir Technologies Inc — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Palantir Technologies Inc trades at $209.05 (market cap $477.68B). The key difference: Palantir Technologies Inc is far larger — about 28.4× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 41,744,992). Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Palantir Technologies Inc for 78 Days on average.
| MEDP | PLTR | |
|---|---|---|
Market Cap | $16.82B | $477.68B |
Volume | 223,093 | 41,744,992 |
Sector | Health | Technology |
52-Week High | $630.19 | $209.05 |
52-Week Low | $393.42 | $107.27 |
Typical Hold Time | 14 Days | 78 Days |
Enterprise Value | $16.44B | $468.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Palantir (PLTR) trades at $198.78, up 2.44% today, showing strong momentum with nine consecutive earnings beats. The stock exhibits bullish technical signals with current price near pivot point resistance at $199. Fundamentally, revenue grew 56.2% to $4.48B in 2025 with net income margin expanding to 36.3%, though valuation metrics remain elevated with P/E of 169.9 and P/S of 83.02. Recent partnership with Armada for sovereign AI infrastructure highlights ongoing business development.
Outlook remains positive given accelerating AI adoption and strong execution, but premium valuation and technical overbought conditions warrant caution. Key risks include growth normalization and competitive pressures. Analyst consensus is bullish with 54% buy ratings and $191.69 price target, though current price exceeds consensus target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
